The Asthma and Allergy Foundation of America annually ranks U.S. cities to find the allergy capital, from the 100 most ...

The FDA has approved a first-of-its-kind eye drop that addresses a common vision condition. The once-daily drops will treat an age-related condition that causes blurry near vision. The drops are ...

Amblyopia, also known as "lazy eye," is a common eye condition in kids that develops when a child has an eye that does not see well. This is caused by a poor connection between the eye to the brain, ...

Reading glasses might be the next thing to go the way of the flip phone. The FDA just approved VIZZ, a once-daily eye drop that helps you see up close without glasses. That’s a big deal if you’re over ...

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer. Managed Healthcare Executive confirms this ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. The US Food and Drug Administration has approved the first eye drop ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million adults in the US alone, has been approved by the Food and Drug Administration ...

To schedule an appointment, call 214-220-3937 or visit keywhitman.com.

The FDA approved aceclidine 1.44% ophthalmic solution (Vizz) for adults with presbyopia, or age-related blurred near vision, maker Lenz Therapeutics announced on Thursday. It marks the first ...

The U.S. Food and Drug Administration has approved Vizz 1.44% (aceclidine ophthalmic solution) for the treatment of presbyopia in adults. Vizz is the first and only aceclidine-based eye drop to ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near vision associated with aging that affects nearly 130 million American adults.

LUMIFY Preservative Free eye drops are statistically non-inferior to LUMIFY in reducing ocular redness, with similar efficacy and safety profiles. The study involved 380 participants, showing high ...